Inteins as targets for potential antimycobacterial drugs

被引:32
|
作者
Paulus, H
机构
[1] Boston Biomed Res Inst, Watertown, MA 02472 USA
[2] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
关键词
inteins; mycobacterium tuberculosis; antimycobacterial drugs; protein splicing; RecA; DnaB; thymidylate synthase; DNA gyrase; CcdB toxin; green fluorescent protein; drug screening; drug targets; high throughput screening; review;
D O I
10.2741/1195
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein splicing is a self-catalyzed process mediated by inteins. The observation that inteins occur only in microorganisms and that they often interrupt genes that play an essential role in nucleic acid metabolism makes them attractive as potential antibacterial targets. Because mycobacteria are the only intein-containing bacteria associated with human hosts, inteins would represent highly specific antimycobacterial targets. In Mycobacterium tuberculosis, two important proteins of DNA repair and replication, RecA and DnaB, respectively, are interrupted by inteins that must be excised by protein splicing before these proteins can function. This review describes the screening systems for the detection of mutations or inhibitors that interfere with proteins splicing that have been developed and published to date. In three of these experimental system, inteins have been inserted into proteins that are toxic under certain conditions. Protein splicing therefore leads to conditional growth inhibition or cell death and its inhibition can be monitored in terms of bacterial growth. A fourth assay for protein splicing and its inhibition is based on purified proteins and measures the formation of Green Fluorescent Protein or its inhibition. The advantages of inteins as antimycobacterial targets are discussed.
引用
收藏
页码:S1157 / S1165
页数:9
相关论文
共 50 条
  • [21] Potential targets for anti-SARS drugs in the structural proteins from SARS related coronavirus
    Wu, G
    Yan, SM
    PEPTIDES, 2004, 25 (06) : 901 - 908
  • [22] Antimycobacterial Activities of an Edible Mushroom Extract and its Synergy with the Standard Antituberculous Drugs
    Chatterjee, Debasmita
    Halder, Dipankar
    Chakraborty, Urmita
    Dutta, Devarati
    Das, Satadal
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018, 12 (06) : DC37 - DC41
  • [23] Antimycobacterial Drugs Modulate Immunopathogenic Matrix Metalloproteinases in a Cellular Model of Pulmonary Tuberculosis
    Singh, Shivani
    Kubler, Andre
    Singh, Utpal K.
    Singh, Ajay
    Gardiner, Harriet
    Prasad, Rajniti
    Elkington, Paul T.
    Friedland, Jon S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4657 - 4665
  • [24] Mycobacterium tuberculosis β-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs
    Aspatwar, Ashok
    Kairys, Visvaldas
    Rala, Sangeetha
    Parikka, Mataleena
    Bozdag, Murat
    Carta, Fabrizio
    Supuran, Claudiu T.
    Parkkila, Seppo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (20)
  • [25] New targets and drugs in cancer chemotherapy
    Szekeres, T
    Novotny, L
    MEDICAL PRINCIPLES AND PRACTICE, 2002, 11 (03) : 117 - 125
  • [26] Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
    Muregi, Francis W.
    Wamakima, Hannah Nyakio
    Kimani, Francis T.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (24) : 3505 - 3521
  • [27] Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs
    Pfeiffer, Ruth M.
    Mayer, Bernd
    Kuncl, Ralph W.
    Check, David P.
    Cahoon, Elizabeth K.
    Rivera, Donna R.
    Freedman, D. Michal
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2020, 21 (3-4) : 235 - 245
  • [28] Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds
    Alvin, Alfonsus
    Miller, Kristin I.
    Neilan, Brett A.
    MICROBIOLOGICAL RESEARCH, 2014, 169 (7-8) : 483 - 495
  • [29] Novel fatty acid-thiadiazole derivatives as potential antimycobacterial agents
    Mali, Jaishree K.
    Sutar, Yogesh B.
    Pahelkar, Akshata R.
    Verma, Preeti M.
    Telvekar, Vikas N.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2020, 95 (01) : 174 - 181
  • [30] Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents
    Zitko, Jan
    Mindlova, Alzbeta
    Valasek, Ondrej
    Jand'ourek, Ondrej
    Paterova, Pavla
    Janousek, Jiri
    Konecna, Klara
    Dolezal, Martin
    MOLECULES, 2018, 23 (09):